<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35088843</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>19</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts.</ArticleTitle><Pagination><StartPage>4425</StartPage><EndPage>4439</EndPage><MedlinePgn>4425-4439</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awac025</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease lacking effective treatments. This is due, in part, to a complex and incompletely understood pathophysiology. To shed light, we conducted untargeted metabolomics on plasma from two independent cross-sectional ALS cohorts versus control participants to identify recurrent dysregulated metabolic pathways. Untargeted metabolomics was performed on plasma from two ALS cohorts (cohort 1, n = 125; cohort 2, n = 225) and healthy controls (cohort 1, n = 71; cohort 2, n = 104). Individual differential metabolites in ALS cases versus controls were assessed by Wilcoxon, adjusted logistic regression and partial least squares-discriminant analysis, while group lasso explored sub-pathway level differences. Adjustment parameters included age, sex and body mass index. Metabolomics pathway enrichment analysis was performed on metabolites selected using the above methods. Additionally, we conducted a sex sensitivity analysis due to sex imbalance in the cohort 2 control arm. Finally, a data-driven approach, differential network enrichment analysis (DNEA), was performed on a combined dataset to further identify important ALS metabolic pathways. Cohort 2 ALS participants were slightly older than the controls (64.0 versus 62.0 years, P = 0.009). Cohort 2 controls were over-represented in females (68%, P &lt; 0.001). The most concordant cohort 1 and 2 pathways centred heavily on lipid sub-pathways, including complex and signalling lipid species and metabolic intermediates. There were differences in sub-pathways that were enriched in ALS females versus males, including in lipid sub-pathways. Finally, DNEA of the merged metabolite dataset of both ALS and control cohorts identified nine significant subnetworks; three centred on lipids and two encompassed a range of sub-pathways. In our analysis, we saw consistent and important shared metabolic sub-pathways in both ALS cohorts, particularly in lipids, further supporting their importance as ALS pathomechanisms and therapeutics targets.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-8780-6637</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savelieff</LastName><ForeName>Masha G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakowski</LastName><ForeName>Stacey A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habra</LastName><ForeName>Hani</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Computational Medicine &amp; Bioinformatics, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karnovsky</LastName><ForeName>Alla</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7388-8520</Identifier><AffiliationInfo><Affiliation>Department of Computational Medicine &amp; Bioinformatics, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hur</LastName><ForeName>Junguk</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of North Dakota, Grand Forks, ND, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><Identifier Source="ORCID">0000-0002-9162-2694</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 TS000289</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES030049</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 ES027221</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1U01CA235487</GrantID><Acronym>BC</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">differential network enrichment analysis</Keyword><Keyword MajorTopicYN="N">lipidomics</Keyword><Keyword MajorTopicYN="N">metabolomics</Keyword><Keyword MajorTopicYN="N">sphingolipids</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>28</Day><Hour>8</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35088843</ArticleId><ArticleId IdType="pmc">PMC9762943</ArticleId><ArticleId IdType="doi">10.1093/brain/awac025</ArticleId><ArticleId IdType="pii">6516342</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman SA. Diagnosis and clinical management of amyotrophic lateral sclerosis and other motor neuron disorders. Continuum (Minneap Minn). 2017;23(5):1332&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">28968365</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17(1):94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Chen KS, Paez-Colasante X, Feldman EL. Emerging understanding of the genotype-phenotype relationship in amyotrophic lateral sclerosis. Handb Clin Neurol. 2018;148:603&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">29478603</ArticleId></ArticleIdList></Reference><Reference><Citation>Paez-Colasante X, Figueroa-Romero C, Sakowski SA, Goutman SA, Feldman EL. Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. Nat Rev Neurol. 2015;11(5):266&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">25896087</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Boss J, Patterson A, Mukherjee B, Batterman S, Feldman EL. High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(8):907&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625908</ArticleId><ArticleId IdType="pubmed">30760645</ArticleId></ArticleIdList></Reference><Reference><Citation>Su FC, Goutman SA, Chernyak S, et al. . Association of environmental toxins with amyotrophic lateral sclerosis. JAMA Neurol. 2016;73(7):803&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5032145</ArticleId><ArticleId IdType="pubmed">27159543</ArticleId></ArticleIdList></Reference><Reference><Citation>Baharum SN, Azizan KA. Metabolomics in systems biology. Adv Exp Med Biol. 2018;1102:51&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">30382568</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Patin F, Madji Hounoum B, et al. . Metabolomics in amyotrophic lateral sclerosis: how far can it take us? Eur J Neurol. 2016;23(3):447&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">26822316</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassina P, Peluffo H, Pehar M, et al. . Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis. J Neurosci Res. 2002;67(1):21&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">11754077</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Yu J, Sardi SP, Shihabuddin LS. Sterol auto-oxidation adversely affects human motor neuron viability and is a neuropathological feature of amyotrophic lateral sclerosis. Sci Rep. 2021;11(1):803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804278</ArticleId><ArticleId IdType="pubmed">33436868</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;7(4):247&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozen S, Cudkowicz ME, Bogdanov M, et al. . Metabolomic analysis and signatures in motor neuron disease. Metabolomics. 2005;1(2):101&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553219</ArticleId><ArticleId IdType="pubmed">18820733</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, Zhang Z, O&#x2019;Reilly &#xc9;J, et al. . Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. 2019;92(18):e2089&#x2013;e2100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6512888</ArticleId><ArticleId IdType="pubmed">30926684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, Brown MV, Alexander D, et al. . Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5&#x2013;6):362&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">24984169</ArticleId></ArticleIdList></Reference><Reference><Citation>Krokidis MG. Transcriptomics and metabolomics in amyotrophic lateral sclerosis. Adv Exp Med Biol. 2020;1195:205&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">32468479</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Veyrat-Durebex C, Bocca C, et al. . Lipidomics reveals cerebrospinal-fluid signatures of ALS. Sci Rep. 2017;7(1):17652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732162</ArticleId><ArticleId IdType="pubmed">29247199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves-Filho AB, Pinto IFD, Dantas LS, et al. . Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):11642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6691112</ArticleId><ArticleId IdType="pubmed">31406145</ArticleId></ArticleIdList></Reference><Reference><Citation>Patin F, Corcia P, Vourc&#x2019;h P, et al. . Omics to explore amyotrophic lateral sclerosis evolution: the central role of arginine and proline metabolism. Mol Neurobiol. 2017;54(7):5361&#x2013;5374.</Citation><ArticleIdList><ArticleId IdType="pubmed">27590138</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A, Jonsson P, Ahnlund M, et al. . Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson&#x2019;s disease and control subjects. Mol Biosyst. 2016;12(4):1287&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">26883206</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Nadal-Desbarats L, Pradat PF, et al. . Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression. Eur J Neurol. 2016;23(2):346&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">26508442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Bala L, Kalita J, et al. . Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clin Chim Acta. 2010;411(7&#x2013;8):563&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">20096678</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Boss J, Guo K, et al. . Untargeted metabolomics yields insight into ALS disease mechanisms. J Neurol Neurosurg Psychiatry. 2020;91:1329&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677469</ArticleId><ArticleId IdType="pubmed">32928939</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer GR, Wigginton J, Duren W, et al. . Application of differential network enrichment analysis for deciphering metabolic alterations. Metabolites. 2020;10(12):479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7761243</ArticleId><ArticleId IdType="pubmed">33255384</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee EP, Cheng S, Larson MG, et al. . Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest. 2011;121(4):1402&#x2013;1411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069773</ArticleId><ArticleId IdType="pubmed">21403394</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewczas MA, Sirich TL, Mathew AV, et al. . Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int. 2014;85(5):1214&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4072128</ArticleId><ArticleId IdType="pubmed">24429397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A, Hedenstr&#xf6;m M, Moritz T, Marklund SL, Antti H, Andersen PM. Optimization of procedures for collecting and storing of CSF for studying the metabolome in ALS. Amyotroph Lateral Scler. 2009;10(4):229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">19412814</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehaven CD, Evans AM, Dai H, Lawton KA. Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminform. 2010;2(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2984397</ArticleId><ArticleId IdType="pubmed">20955607</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans AM, Bridgewater B, Liu Q, et al. . High resolution mass spectrometry improves data quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput profiling metabolomics. Metabolomics. 2014;4(2):1000132.</Citation></Reference><Reference><Citation>Do KT, Wahl S, Raffler J, et al. . Characterization of missing values in untargeted MS-based metabolomics data and evaluation of missing data handling strategies. Metabolomics. 2018;14(10):128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6153696</ArticleId><ArticleId IdType="pubmed">30830398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohart F, Gautier B, Singh A, Le Cao KA. mixOmics: An R package for &#x2018;omics feature selection and multiple data integration. PLoS Comput Biol. 2017;13(11):e1005752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5687754</ArticleId><ArticleId IdType="pubmed">29099853</ArticleId></ArticleIdList></Reference><Reference><Citation>Galindo-Prieto B, Eriksson L, Trygg J. Variable influence on projection (VIP) for orthogonal projections to latent structures (OPLS). J Chemom. 2014;28(8):623&#x2013;632.</Citation></Reference><Reference><Citation>Cho HW, Kim SB, Jeong MK, et al. . Discovery of metabolite features for the modelling and analysis of high-resolution NMR spectra. Int J Data Min Bioinform. 2008;2(2):176&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883573</ArticleId><ArticleId IdType="pubmed">18767354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Karnovsky A, Afshinnia F, et al. . Differential network enrichment analysis reveals novel lipid pathways in chronic kidney disease. Bioinformatics. 2019;35(18):3441&#x2013;3452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748777</ArticleId><ArticleId IdType="pubmed">30887029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Shojaie A, Michailidis G. Network-based pathway enrichment analysis with incomplete network information. Bioinformatics. 2016;32(20):3165&#x2013;3174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939912</ArticleId><ArticleId IdType="pubmed">27357170</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, Cudkowicz ME, Brown MV, et al. . Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012;13(1):110&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">22117131</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Goutman SA, Boss J, Kim S, Feldman EL. Amyotrophic lateral sclerosis survival associates with neutrophils in a sex-specific manner. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057067</ArticleId><ArticleId IdType="pubmed">33531377</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Famie JP, Piecuch CE, et al. . Natural killer cells associate with amyotrophic lateral sclersois in a sex- and age-dependent manner. JCI Insight. 2021;6:e147129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262328</ArticleId><ArticleId IdType="pubmed">33974561</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape JA, Grose JH. The effects of diet and sex in amyotrophic lateral sclerosis. Rev Neurol (Paris). 2020;176(5):301&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8915943</ArticleId><ArticleId IdType="pubmed">32147204</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyene HB, Olshansky G AATS, et al. . High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies. PLoS Biol. 2020;18(9):e3000870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7544135</ArticleId><ArticleId IdType="pubmed">32986697</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa M, Maekawa K, Saito K, et al. . Plasma and serum lipidomics of healthy white adults shows characteristic profiles by subjects&#x2019; gender and age. PLoS One. 2014;9(3):e91806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3954792</ArticleId><ArticleId IdType="pubmed">24632803</ArticleId></ArticleIdList></Reference><Reference><Citation>Veyrat-Durebex C, Bris C, Codron P, et al. . Metabo-lipidomics of fibroblasts and mitochondrial-endoplasmic reticulum extracts from ALS patients shows alterations in purine, pyrimidine, energetic, and phospholipid metabolisms. Mol Neurobiol. 2019;56(8):5780&#x2013;5791.</Citation><ArticleIdList><ArticleId IdType="pubmed">30680691</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Croixmarie V, Priestman DA, et al. . Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. Hum Mol Genet. 2015;24(25):7390&#x2013;7405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664174</ArticleId><ArticleId IdType="pubmed">26483191</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52(4):448&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Treleaven CM, Pacheco J, et al. . Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2015;112(26):8100&#x2013;8105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491749</ArticleId><ArticleId IdType="pubmed">26056266</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Croixmarie V, Bouscary A, et al. . Sphingolipid metabolism is dysregulated at transcriptomic and metabolic levels in the spinal cord of an animal model of amyotrophic lateral sclerosis. Front Mol Neurosci. 2018;10:433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5758557</ArticleId><ArticleId IdType="pubmed">29354030</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohassel P, Donkervoort S, Lone MA, et al. . Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat Med. 2021;27(7):1197&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9309980</ArticleId><ArticleId IdType="pubmed">34059824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Bieberich E. Sphingolipids in neurodegeneration (with focus on ceramide and S1P). Adv Biol Regul. 2018;70:51&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251739</ArticleId><ArticleId IdType="pubmed">30287225</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaurasia B, Summers SA. Ceramides - Lipotoxic inducers of metabolic disorders. Trends Endocrinol Metab. 2015;26(10):538&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">26412155</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S, Snider AJ. Sphingolipids in high fat diet and obesity-related diseases. Mediators Inflamm. 2015;2015:520618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4663345</ArticleId><ArticleId IdType="pubmed">26648664</ArticleId></ArticleIdList></Reference><Reference><Citation>Deevska GM, Nikolova-Karakashian MN. The twists and turns of sphingolipid pathway in glucose regulation. Biochimie. 2011;93(1):32&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3006650</ArticleId><ArticleId IdType="pubmed">20561942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibellini F, Smith TK. The Kennedy pathway&#x2013;De novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life. 2010;62(6):414&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">20503434</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracey TJ, Steyn FJ, Wolvetang EJ, Ngo ST. Neuronal lipid metabolism: Multiple pathways driving functional outcomes in health and disease. Front Mol Neurosci. 2018;11:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5787076</ArticleId><ArticleId IdType="pubmed">29410613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball W B, Neff JK, Gohil VM. The role of nonbilayer phospholipids in mitochondrial structure and function. FEBS Lett. 2018;592(8):1273&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5918238</ArticleId><ArticleId IdType="pubmed">29067684</ArticleId></ArticleIdList></Reference><Reference><Citation>Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106(8):1319&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877591</ArticleId><ArticleId IdType="pubmed">20431074</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Preux PM, Magy L, et al. . Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001;74(3):328&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauckneht M, Lai R, Miceli A, et al. . Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: a computational approach to [18F]-fluorodeoxyglucose PET/CT images. EJNMMI Res. 2020;10(1):23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7085992</ArticleId><ArticleId IdType="pubmed">32201914</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eunen K, Simons SM, Gerding A, et al. . Biochemical competition makes fatty-acid beta-oxidation vulnerable to substrate overload. PLoS Comput Biol. 2013;9(8):e1003186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3744394</ArticleId><ArticleId IdType="pubmed">23966849</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergani A, Oudart H, De Aguilar JLG, et al. . Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J Lipid Res. 2007;48(7):1571&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1974855</ArticleId><ArticleId IdType="pubmed">17438338</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Ren&#xe9; F, de Aguilar JLG, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A. 2004;101(30):11159&#x2013;11164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharaoh G, Sataranatarajan K, Street K, et al. . Metabolic and stress response changes precede disease onset in the spinal cord of mutant SOD1 ALS mice. Front Neurosci. 2019;13:487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554287</ArticleId><ArticleId IdType="pubmed">31213966</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E, O&#x2019;Conner AG, Barrows JM, Shreiner DD, Birchak GJ, Zarnescu DC. Medium-chain fatty acids, beta-hydroxybutyric acid and genetic modulation of the carnitine shuttle are protective in a drosophila model of ALS based on TDP-43. Front Mol Neurosci. 2018;11:182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990617</ArticleId><ArticleId IdType="pubmed">29904341</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E, Lorenzini I, Barrameda D, et al. . Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. eLife. 2019;8:e45114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6557627</ArticleId><ArticleId IdType="pubmed">31180318</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Corcia P, Moreau C, et al. . 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS One. 2010;5(10):e13223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951909</ArticleId><ArticleId IdType="pubmed">20949041</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, Hashizume A, Hijikata Y, et al. . Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. J Neurol. 2019;266(12):2952&#x2013;2961.</Citation><ArticleIdList><ArticleId IdType="pubmed">31456060</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena GN, Rizzardini M, Cimini S, et al. . Metabolomic analysis reveals increased aerobic glycolysis and amino acid deficit in a cellular model of amyotrophic lateral sclerosis. Mol Neurobiol. 2016;53(4):2222&#x2013;2240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823370</ArticleId><ArticleId IdType="pubmed">25963727</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Lanznaster D, Veyrat-Durebex C, et al. . Understanding and managing metabolic dysfunction in Amyotrophic Lateral Sclerosis. Expert Rev Neurother 2020;20(9):907&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">32583696</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, Li R, Kirk SE, et al. . Altered skeletal muscle glucose-fatty acid flux in amyotrophic lateral sclerosis. Brain Commun. 2020;2(2):fcaa154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677608</ArticleId><ArticleId IdType="pubmed">33241210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera TW, Borges K. Metabolic dysfunctions in amyotrophic lateral sclerosis pathogenesis and potential metabolic treatments. Front Neurosci. 2017;10:611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5222822</ArticleId><ArticleId IdType="pubmed">28119559</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiduschat N, Mao X, Hupf J, et al. . Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique. Neurosci Lett. 2014;570:102&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">24769125</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Alessandro G, Calcagno E, Tartari S, Rizzardini M, Invernizzi RW, Cantoni L. Glutamate and glutathione interplay in a motor neuronal model of amyotrophic lateral sclerosis reveals altered energy metabolism. Neurobiol Dis. 2011;43(2):346&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">21530659</ArticleId></ArticleIdList></Reference><Reference><Citation>Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(1):9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11465936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, et al. . ALS phenotype is influenced by age, sex, and genetics: A population-based study. Neurology. 2020;94(8):e802&#x2013;e810.</Citation><ArticleIdList><ArticleId IdType="pubmed">31907290</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida S, Mulder DW, Kurland LT, Chu CP, Okazaki H. Follow-up study on amyotrophic lateral sclerosis in Rochester, Minn., 1925 through 1984. Neuroepidemiology. 1986;5(2):61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">3785524</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>